

## **SWIXX AND JAZZ PHARMACEUTICALS EXPAND PARTNERSHIP WITH AGREEMENT TO NOW DISTRIBUTE EPIDYOLEX® (CANNABIDIOL) IN CEE TERRITORIES**

**SWIXX ANNOUNCEMENT NO. 51**

**January 20<sup>th</sup>, 2023**

**Baar, Switzerland** – Swixx BioPharma AG of Baar, Switzerland, announced today an extension of its collaboration with Jazz Pharmaceuticals Ireland Limited and GW Pharma (International) B.V. Jazz had previously appointed Swixx as exclusive distributor to import, use, market, sell and distribute Defitelio® (defibrotide) and Vyxeos® (daunorubicin and cytarabine liposomal) in Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovenia and Slovakia. With the new arrangement, as of January 1<sup>st</sup>, 2023, Swixx also becomes the exclusive distributor of Epidyolex® (cannabidiol) in the same territories with the additional territories of Greece, Cyprus\* and Malta.

Epidyolex® (cannabidiol) is indicated for the adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS), in conjunction with clobazam, for patients two years of age and older. Epidyolex® is also indicated for the adjunctive therapy of seizures associated with Tuberous Sclerosis Complex (TSC) for patients two years of age and older.<sup>1</sup>

“We are very pleased to expand our successful partnership with Jazz Pharmaceuticals to include Epidyolex,” commented Swixx COO, Dr. Dezsó Martha. “We look forward to working with Jazz to assist and bring relief to patients living with Lennox-Gastaut, Dravet syndrome and tuberous sclerosis complex. We hope that with Swixx’s strong, Southern Europe and pan-CEE presence and by working in close engagement with the neurology healthcare community we can find a swift way to improve access to Epidyolex® for CEE patients.”

### **About Swixx BioPharma AG**

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian Economic Union countries plus Moldova and Uzbekistan. With over 1200 employees and sales likely to exceed 700M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE and Eurasia. The company has gathered outstanding rare disease, oncology-haematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com)

**Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG**

[vedrana.sokac@swixxbiopharma.com](mailto:vedrana.sokac@swixxbiopharma.com), Tel: +385 1 425 6086

\*In Cyprus, Jazz is committed to supplying Epidyolex to an authorized reseller for onward supply and fulfilment of a tender award by the Cypriot Government which will remain in effect until 1st April 2023.

<sup>1</sup>European Medicines Agency, Summary of Product Characteristics Epidyolex. Available at:

[https://www.ema.europa.eu/en/documents/product-information/epidyolex-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/epidyolex-epar-product-information_en.pdf); last accessed: December 2022.